Introduction: A large group of lymph node-positive breast cancer patients receive neoadjuvant chemotherapy and subsequently undergo axillary lymph node dissection. It has been previously proposed that axillary lymph node dissection may be avoided -and it's associated reduced morbidity -in patients showing pathologic complete response. Therefore, the purpose of this study was to develop a nomogram to predict axillary node pathologic response to neoadjuvant chemotherapy in breast cancer patients in order to guide the surgical treatment decision-making process for this group of patients. Methods: A cross-sectional, secondary data study was carried out between 2013-2016 on 222 lymph node-positive breast cancer patients who received neoadjuvant chemotherapy followed by locoregional management, including axillary lymph node dissection. Logistic regression analysis was performed to determine the association of the axillary pathologic complete response with the different clinical and pathological variables. Variables found to be statistically significantly associated with axillary pCR (pathologic complete response) were used to create the logistic regression model and the nomogram in pre-menopausal patients. Axillary pCR was defined as absence of residual disease in the breast and of micro-metastasis in axillary lymph nodes. Samples with isolated tumor cells were considered as positive for residual disease. Results: a total of 222 patients were included, of which 131 were premenopausal at the time of diagnosis. Axillary pathologic complete response was observed in 55.7% (73 of 131) of patients, and was significantly associated with estrogen receptor (ER) negative tumors (OR 2.59, 95%CI 1.21-5.53), progesterone receptor (PR) negative tumors (OR 2.63, 95%CI 1.28-5.38), and Her2 positive tumors (OR 0.40,, for which a significant correlation with increased probability of achieving axillary pathologic complete response was evidenced. Conclusion: The performance of this model to predict axillary pCR in pre-menopausal patients was weak, and therefore the decision to avoid surgical axillary dissection should not be based solely on the developed nomogram. However, further studies may lead to validation of this model.
INTRODUCTION
Determining lymph node involvement in breast cancer patients provides prognostic information and helps the treatment decisionmaking process for these patients 1 . Axillary lymph node-positive breast cancer patients are frequently subjected to neoadjuvant chemotherapy (NAC), of which 20% to 60% achieve axillary pathologic complete response (pCR) [1] [2] [3] [4] [5] [6] [7] . However, despite of the extent of pathologic response achieved with chemotherapy, axillary lymph node dissection continues to be considered the gold standard treatment for patients with axillary lymph node involvement 8 . Patients achieving axillary pCR have been shown to have better prognosis, and it has thus been proposed that in those patients achieving pCR, axillary lymph node dissection and its associated short and long term morbidities -such as lymphedema and reduced shoulder range of motion -could have been avoided 9, 10 . Currently, there are no available methods to identify patients in whom this procedure could be avoided without negatively impacting survival 11 . Therefore, there is a need to identify factors that could be used to predict axillary node pathologic response after systemic neoadjuvant chemotherapy. Hence, the goal of this study was to identify variables and develop a model that could predict axillary pCR in Latin-American breast cancer patients.
MATERIALS AND METHODS

Ethics
The ethics committee of the Colombian Foundation for Cancer, Clinica Vida, approved this study.
Study population
This was a cross-sectional, secondary data study carried out between 2013-2016. A total of 222 pre-and postmenopausal patients with stage T1-4 breast cancer, with axillary involvement confirmed by biopsy, and treated with neoadjuvant chemotherapy followed by locoregional management, including axillary lymph node dissection, were included in this study. Patients with bilateral breast cancer, inflammatory breast cancer, inadequate disease staging, pregnancy, or history of previous axillary surgery were excluded from this study.
Data collection and analysis
Clinical and pathological reports were reviewed to determine diagnosis before neoadjuvant treatment. Biopsies of primary tumors were analyzed using standard hematoxylin and eosin (H&E) staining, and Bloom-Richardson staging system was used to classify histological grade. Estrogen receptor (ER) and progesterone receptor (PR) status was determined by immunohistochemistry (IHC), and reported as percentage of positive cells. Human epidermal growth factor receptor-2 (HER-2) overexpression was defined as positive either by a score of +3 by immunohistochemistry, or a score ≥2 by fluorescent in situ hybridization (FISH). Breast imaging reports were reviewed to determine tumor size, multicentricity, or multifocality. Clinical tumor-node-metastasis (TNM) cancer staging was performed according to the 7 th edition of the American Joint Committee on Cancer . Data on lymph node status after neoadjuvant chemotherapy was extracted from the pathological report after axillary lymph node dissection.
RESUMEN
Introdução: Um grande grupo de pacientes com câncer de mama linfonodo-positivo recebe quimioterapia neoadjuvante, que subsequentemente são submetidos a dissecção de linfonodos axilares. Foi proposto anteriormente que a dissecção de linfonodos axilares pode ser evitada -assim como a redução de sua morbidade -em pacientes que apresentam resposta patológica completa. Portanto, o objetivo deste estudo foi desenvolver um nomograma para prever a resposta patológica do linfonodo axilar à quimioterapia neoadjuvante em pacientes com câncer de mama, a fim de orientar o processo de decisão do tratamento cirúrgico para este grupo de pacientes. Metodologia: Foi realizado um estudo transversal, de dados secundários, entre os anos de 2013-2016 em 222 pacientes com câncer de mama linfonodo-positivo, que receberam quimioterapia neoadjuvante seguida de tratamento locorregional, incluindo dissecção de linfonodos axilares. A análise de regressão logística foi realizada para determinar a associação da resposta completa patológica axilar com as diferentes variáveis clínicas e patológicas. Variáveis estatisticamente associadas à pCR axilar (resposta completa patológica) foram usadas para criar o modelo de regressão logística e nomograma em pacientes na pré-menopausa. A pCR axilar foi definida como ausência de doença residual na mama e de micro-metástase nos linfonodos axilares. Amostras com células tumorais isoladas foram consideradas positivas para doença residual. Resultados: foram incluídos 222 pacientes, dos quais 131 estavam na pré-menopausa no momento do diagnóstico. A resposta patológica axilar completa foi observada em 55,7% (73 de 131) dos pacientes, e foi significativamente associada a tumores negativos para receptores de estrogênio(RE) (OR 2,59; IC 95% 1,21-5,53) e negativos para receptores de progesterona (RP) (OR 2.63, IC 95% 1.28-5.38), e Her2 positivos (OR 0.40, IC 95% 0.19-0.84), para o qual foi evidenciada uma correlação significativa com o aumento da probabilidade de atingir resposta completa patológica axilar. Conclusão: O desempenho deste modelo para prever a pCR axilar em pacientes na pré-menopausa era fraco e, portanto, a decisão de evitar a dissecção axilar cirúrgica não deve ser baseada apenas no nomograma desenvolvido. No entanto, estudos posteriores podem levar à validação desse modelo.
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Statistical analysis
The quantitative variables were presented as means with their respective dispersion measures according to the distribution of the variables. Qualitative variables are shown as percentages. Student's t test was performed to compare means for independent samples. Group comparisons were performed using Chi-squared test (χ 2 ). A p value <0.05 was considered statistically significant. Logistic regression analysis was performed to determine the association of the axillary pathologic complete response with the different clinical and pathological variables. Variables found to be statistically significantly associated with axillary pCR were used to create the logistic regression model and the nomogram in pre-menopausal patients. Estrogen receptor status was analyzed as a binary variable. Axillary cPR was defined as absence of residual disease in the breast and of micro-metastasis in axillary lymph nodes. Samples with isolated tumor cells were considered as positive for residual disease.
RESULTS
The study included 222 patients with breast cancer, who had axillary lymph node involvement and were treated with neoadjuvant chemotherapy. The clinical pathological features are listed in Table 1 . Of all patients, 59% were pre-menopausal, 78% had lymphovascular invasion, 41.4% were T4 tumors, and 36.4% were Her2 positive tumors. In the univariate analysis of the entire study population -which was stratified in pre-and post-menopausal -, only in the premenopausal subgroup, a significant impact in predicting the axillary response was demonstrated through a logistic regression model (data not shown). Tables 2 and 3 show factors associated with the achievement of axillary pCR in pre-menopausal patients who underwent axillary lymph node dissection after neoadjuvant chemotherapy, and of which axillary pCR was observed in 55.7% of the cases (73 of 131).
Patients with T4 disease showed a higher probability of residual axillary lymph node disease. Axillary pCR was a significant correlation with increased probability of achieving axillary pathologic complete response in patients with ER-negative tumors (OR 2.59, 95%CI 1.21-5.53), PR-negative tumors (OR 2.63, 95%CI 1.28-5.38), and Her2-positive status (OR 0.40, 95%CI 0.19-0.84), for which a significant correlation with increased probability of achieving axillary pathologic complete response was evidenced.
These variables (ER-, PR-, Her2 status) were used in the multivariate logistic regression analysis model that correlated with an increase in the probability of achieving axillary complete pathologic response (Table 3 ). The resulting nomogram for predicting axillary complete pathologic response in premenopausal patients after neoadjuvant chemotherapy was generated based on variables with statistical significance, and three variables of clinical significance were also included (Figures 1 and 2) . 
DISCUSSION
In the context of breast cancer, axillary lymph node status has been shown to be an important prognostic factor that also guides treatment of these patients. Therefore, accurate nodal staging is essential for planning of appropriate breast cancer therapy 1 . Previously, several studies have reported different preoperative tools to determine axillary treatment options for axillary lymph node-positive breast cancer patients receiving neoadjuvant chemotherapy 12, 13 . One of such tools are nomograms, which have been evaluated in breast cancer patients with axillary lymph node involvement in order to identify those patients presenting pathologic complete response of axillary lymph nodes to neoadjuvant chemotherapy, as well as to identify patients in which axillary lymph node dissection could be avoided [14] [15] [16] [17] . In this study, we identified variables associated with axillary node pathologic complete response (pCR) to the use of neoadjuvant chemotherapy in pre-menopausal lymph node-positive breast cancer patients. In our study, the majority (90%) of chemotherapeutic regimens were anthracycline and taxane based, and axillary cPR was evidence in 55.7% of cases. This is comparable to the 20% to 60% pCR range previously reported by others [1] [2] [3] [4] [5] [6] . Our data suggest that clinical stage, hormone receptor status, and Her2 status are relevant variables to predict pathologic response to systemic treatment in premenopausal breast cancer patients. This observations are in agreement with previous studies in which a greater response to therapy was observed in tumors of the triple negative (ER-/PR-/Her2-) and HER2 positive subtypes, followed by luminal A and B subtypes, albeit to a lesser extent 2, 8, 9 . In addition, using the Surveillance, Epidemiology, and End Results (SEER) registry, Mattes and colleagues showed that breast cancer subtype is an independent risk factor for lymph node positivity, and for the response to neoadjuvant chemotherapy [18] [19] [20] . In this analysis, the vast majority of the available clinicalpathological variables in the preoperative context were considered. Our model predicts a complete pathologic response of 34% in premenopausal patients. To our knowledge, this is the first predictive model developed for axillary node pCR after neoadjuvant chemotherapy in a significant number of premenopausal patients. However, this result does not support the modification of the current recommendations in widely accepted clinical guidelines for the management of patients with lymph node involvement prior to neoadjuvant chemotherapy.
Our study presents some limitations including its retrospective nature, as well as the fact that the study population comprised a cohort from a single center. Thus, external validation of this model using independent cohorts is necessary before the nomograms can be applied in the clinical setting. On the other hand, while many of the analyzed factors are routinely obtained in the clinic, this may be challenging in some settings and render the nomograms without any practical value.
While the performance of this predictive model of axillary node pCR in premenopausal patients was weak in our study population, and the decision to avoid surgical axillary dissection cannot be currently based solely on this nomogram, future studies may validate our model and provide a tool that may ultimately contribute to improve care of breast cancer patients. 
